Sanofi reported net cash proceeds of about 10 billion ($10.7 billion) from the deal, which it had outlined earlier in 2024.

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2Stay Ahead of the Market: Discover outperforming ...

Sanofi confirms the expectation of a strong ... the upcoming closing of the sale of a majority stake in Opella and the recent acquisition of a bispecific myeloid cell engager for deep B-cell ...

In October 2023, Sanofi announced its intention to separate its Consumer Healthcare (CHC) unit through the creation of a publicly listed entity headquartered in Paris to be called Opella.

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling ...

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up ...